US Patent

US11498913 — Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors

Formulation · Assigned to Forma Therapeutics Inc · Expires 2035-09-18 · 9y remaining

Vulnerability score 50/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a class of compounds that inhibit mutant isocitrate dehydrogenase proteins, useful in treating cell-proliferation disorders and cancers.

USPTO Abstract

The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, U, W 1 , W 2 , W 3 , R 1 -R 6 , and R 9 are described herein.

Drugs covered by this patent

Patent Metadata

Patent number
US11498913
Jurisdiction
US
Classification
Formulation
Expires
2035-09-18
Drug substance claim
No
Drug product claim
Yes
Assignee
Forma Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.